Financial comparison: Q BioMed (OTCMKTS: QBIO) vs Paratek Pharmaceuticals (NASDAQ: PRTK)


Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and Q BioMed (OTCMKTS:QBIO – Get Rating) are both small cap medical companies, but which is the best investment? We’ll compare the two companies based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Benefits and evaluation

This table compares the revenue, earnings per share and valuation of Paratek Pharmaceuticals and Q BioMed.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Paratek Pharmaceuticals $130.16 million 1.10 -$59.08 million ($1.69) -1.55
Q BioMed $200,000.00 6.56 -8.24 million dollars ($0.29) -0.10

Q BioMed has lower revenues, but higher profits than Paratek Pharmaceuticals. Paratek Pharmaceuticals trades at a lower price-to-earnings ratio than Q BioMed, indicating that it is currently the more affordable of the two stocks.

Volatility and risk

Paratek Pharmaceuticals has a beta of 1.52, which means its stock price is 52% more volatile than the S&P 500. In comparison, Q BioMed has a beta of 2.19, which means its stock price is 119 % more volatile than the S&P 500.

Analyst Notes

This is a summary of current recommendations and price targets for Paratek Pharmaceuticals and Q BioMed, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Paratek Pharmaceuticals 0 0 1 1 3.50
Q BioMed 0 0 0 0 N / A

Paratek Pharmaceuticals currently has a consensus target price of $15.50, suggesting a potential upside of 491.60%. Considering the higher possible upside of Paratek Pharmaceuticals, research analysts clearly believe that Paratek Pharmaceuticals is more favorable than Q BioMed.

Profitability

This table compares the net margins, return on equity and return on assets of Paratek Pharmaceuticals and Q BioMed.

Net margins Return on equity return on assets
Paratek Pharmaceuticals -77.64% N / A -49.13%
Q BioMed -1,868.26% N / A -1,226.46%

Insider and Institutional Ownership

59.5% of Paratek Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Q BioMed shares are held by institutional investors. 8.0% of the shares of Paratek Pharmaceuticals are held by insiders of the company. Strong institutional ownership indicates that endowments, hedge funds, and large fund managers believe a stock is poised for long-term growth.

Summary

Paratek Pharmaceuticals beats Q BioMed on 8 out of 13 factors compared between the two stocks.

About Paratek Pharmaceuticals

(Get an evaluation)

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, is focused on developing and commercializing life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial infections of the skin and skin structures caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases or medical conditions; and a contract with the Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has entered into a license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

About Q BioMed

(Get an evaluation)

Q BioMed Inc., a biomedical development and accelerator company, is focused on licensing, acquiring and providing resources to life science and healthcare companies. The company offers strontium chloride SR89 and Metastron, a radiopharmaceutical therapeutic agent for the treatment of metastatic pain related to bone cancer. It is also developing Man-01, a preclinical candidate for the treatment of primary open-angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorders; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapies to treat acute respiratory distress syndrome, glaucoma, kidney disease and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.



Get news and reviews for Paratek Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.

Margie D. Carlisle